Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) showed similar efficacy in a real-world analysis, consistent with their pivotal trial data, in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL), according to a presentation at the European Society for Blood and Marrow Transplantation annual meeting.
The EBMT analysis was led by first author Anna Ossami Saidy, a doctor in specialist training, of the Department of Hematology and Cell Therapy at Helios Klinikum Berlin-Buch in Germany.
In this reported analysis, investigators evaluated 515 patients with LBCL from the EBMT registry who were treated between January 2022 and December 2024. Of that patient group, 471 received axi-cel, while 44 patients received liso-cel. Most patients were male (64%), had advanced disease with the majority (77%) presenting with stage III–IV disease, and more than half (58%) of patients had refractory disease at the time of infusion.
At one year, survival outcomes were similar between the two groups, with comparable overall survival (OS) and progression-free survival (PFS) and low non-relapse mortality (NRM), the investigators reported. PFS at one year was 60.7% for the entire cohort, 60.3% for patients who received axi-cel, and 64.4% for patients treated with liso-cel.
“In this real-world analysis, patients with r/r LBCL receiving axi-cel or liso-cel infusion in the second line setting achieved excellent 1-year survival outcomes, consistent with pivotal trial data,” the authors wrote in their conclusion. “Both products demonstrated similar results in terms of OS, PFS and RI. NRM is notably low for both axi- and liso-cel, highlighting that both products are not only highly efficacious but also safe.”
This is a summary of the oral EBMT abstract, Comparative efficacy of axicabtagene ciloleucel and lisocabtagene maraleucel in second line treatment of relapsed/refractory large B-cell lymphoma – an EBMT analysis.
